Glipizide and Ilevro drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glipizide (glipizide) and Ilevro (nepafenac). Common drug interactions include acute myocardial infarction among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Glipizide and Ilevro. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Glipizide?

Glipizide has active ingredients of glipizide. It is often used in diabetes. eHealthMe is studying from 64,852 Glipizide users. Check the latest studies of Glipizide.

What is Ilevro?

Ilevro has active ingredients of nepafenac. eHealthMe is studying from 1,531 Ilevro users. Check the latest studies of Ilevro.



On Jul, 21, 2026

11 people who take Glipizide and Ilevro together, and have interactions are studied.

Glipizide and Ilevro drug interactions.

What are the common drug interactions of Glipizide and Ilevro, by gender? *:

female:

  1. Acute myocardial infarction (acute heart attack)
  2. Acute respiratory failure
  3. Aortic valve disease
  4. Aortic valve stenosis (narrowing of the aortic valve)
  5. Cardiac failure acute
  6. Cardiac failure congestive
  7. Cardiogenic shock (inadequate circulation of blood)
  8. Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
  9. Ischaemic cardiomyopathy (weakness in the muscle of the heart due to inadequate oxygen delivery to the myocardium with coronary artery disease)
  10. Cardiac disorder

male:

  1. Chronic kidney disease
  2. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  3. Muscle spasms (muscle contraction)
  4. Scrotal abscess (pus in scrotum)
  5. Urinary tract infection
  6. Weight decreased
  7. White blood cell count decreased

What are the common drug interactions of Glipizide and Ilevro, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Scrotal abscess (pus in scrotum)

50-59:

  1. Chronic kidney disease
  2. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  3. Renal failure (kidney dysfunction)

60+:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Acute left ventricular failure (heart attack)
  3. Ischaemic cardiomyopathy (weakness in the muscle of the heart due to inadequate oxygen delivery to the myocardium with coronary artery disease)
  4. Chronic kidney disease
  5. Drug ineffective
  6. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  7. Muscle spasms (muscle contraction)
  8. Muscular weakness (muscle weakness)
  9. Syncope (loss of consciousness with an inability to maintain postural tone)
  10. Urinary tract infection

What are the existing conditions these people have? *

  1. Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 36.36%
  2. High Blood Pressure: 4 people, 36.36%
  3. Insomnia (sleeplessness): 3 people, 27.27%
  4. Breast Cancer Female: 3 people, 27.27%
  5. Eye Inflammation: 3 people, 27.27%
  6. Type 2 Diabetes: 3 people, 27.27%
  7. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 27.27%
  8. Anaemia (lack of blood): 2 people, 18.18%
  9. Stress And Anxiety: 2 people, 18.18%
  10. Nasopharyngitis (inflammation of the nasopharynx): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Glipizide and Ilevro?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Glipizide and Ilevro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Glipizide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ilevro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Glipizide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ilevro and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on glipizide and nepafenac (the active ingredients of Glipizide and Ilevro, respectively), and Glipizide and Ilevro (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: